Physician profile
Osman Dandan
NPI 1598131799
$731.61
in general payments reported to CMS, 2019-2025
17 companies · $78.29 in 2025
The $78.29 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.96 · 2022: $457 · 2023: $42.93 · 2024: $105 · 2025: $78.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $225.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Viiv Healthcare Company | $120.79 | 2022 | |
| Cranial Technologies, INC | $114.73 | 2021-2025 | Doc Band |
| Sanofi Pasteur INC. | $40.95 | 2022-2023 | |
| Abbvie INC. | $38.77 | 2021-2024 | |
| Alkermes, INC. | $38.15 | 2022 | |
| Neurocrine Biosciences, INC. | $37.53 | 2022 | |
| Novo Nordisk INC | $36.42 | 2022 | |
| Echosens North America, INC. | $24.74 | 2025 | Fibroscan |
| Vanda Pharmaceuticals INC. | $23.68 | 2022 | |
| Lilly USA, LLC | $22.82 | 2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $21.20 | 2024 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.09 | 2022 | |
| Lundbeck LLC | $19.05 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.84 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $13.95 | 2024 | Flucelvax |
| Currax Pharmaceuticals LLC | $13.90 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osman Dandan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.